BIIB
reuters.dev
http://www.google.com/url?source=finance&q=http%3A%2F%2Fwww.reuters.com%2Ffinance%2Fstocks%2FBIIB.O%2Fkey-developments%2Farticle%2F2490346&ei=oIaaUrm3H4Hl0gG83wE&usg=AFQjCNF1pwpxTzX5Ec_Z9Ll8oEcSjmARSw
Biogen Idec Inc Submits Application To FDA For Approval Of Oral BG-12 To Treat Multiple Sclerosis
Tuesday, 28 Feb 2012 08:00am EST
Biogen Idec Inc. announced that the Company has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for marketing approval of BG-12 (dimethyl fumarate), the Company’s oral therapeutic candidate for the treatment of multiple sclerosis (MS). The regulatory submission was based on BG-12’s comprehensive development program, in which BG-12 demonstrated reductions in MS disease activity coupled with favorable safety and tolerability in the Phase 3 DEFINE and CONFIRM studies. Biogen Idec plans to submit a Marketing Authorisation Application (MAA) for BG-12 to the European Medicines Agency (EMA) within the coming days. 
